United Therapeutics (UTHR) Earnings Date, Estimates & Call Transcripts $359.85 +1.32 (+0.37%) (As of 11:15 AM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Earnings SummaryUpcoming Earnings DateNov. 6EstimatedActual EPS (Jul. 31) $5.85 Missed By -$0.48 Consensus EPS (Jul. 31) $6.33 Conference Call TranscriptConference Call AudioEarnings Press ReleaseSEC 10-Q/10-K Filing Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueUTHR Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.UTHR Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Brownstone ResearchAI expert reveals new Nvidia predictionEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released my latest prediction and believe it or not, I’m advising NOT pour all your money into Nvidia right nowClick here to see why United Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242$5.10$5.93$5.52Q2 20243$5.55$6.50$5.92Q3 20243$5.69$7.41$6.33Q4 20242$5.40$7.83$6.62FY 202410$21.74$27.67$24.38Q1 20251$6.59$6.59$6.59Q2 20251$6.36$6.36$6.36Q3 20251$6.26$6.26$6.26Q4 20251$5.65$5.65$5.65FY 20254$24.86$24.86$24.86Q1 20261$6.42$6.42$6.42Q2 20261$6.62$6.62$6.62UTHR Earnings Date and InformationUnited Therapeutics last issued its quarterly earnings data on July 31st, 2024. The biotechnology company reported $5.85 EPS for the quarter, missing analysts' consensus estimates of $6.33 by $0.48. The firm earned $714.90 million during the quarter, compared to analyst estimates of $691.87 million. Its revenue for the quarter was up 19.8% on a year-over-year basis. United Therapeutics has generated $21.15 earnings per share over the last year ($21.15 diluted earnings per share) and currently has a price-to-earnings ratio of 17.0. Earnings for United Therapeutics are expected to grow by 12.08% in the coming year, from $24.84 to $27.84 per share. United Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 6th, 2024 based off prior year's report dates.Read More United Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 11/6/2024(Estimated)------- 7/31/2024Q2 2024$6.33$5.85($0.48)$5.85$691.87 million$714.90 million 5/1/2024Q1 2024$5.63$6.17+$0.54$6.17$620.31 million$677.70 million 2/21/2024Q4 2023$4.28$4.36+$0.08$4.36$575.01 million$614.70 million 11/1/2023Q3 2023$5.10$5.38+$0.28$5.38$585.82 million$609.40 million 8/2/2023Q2 2023$4.57$5.24+$0.67$5.24$524.18 million$596.50 million 5/3/2023Q1 2023$4.26$4.86+$0.60$4.86$514.37 million$506.90 million Most hated message on Wall Street (Ad)If you're a concerned citizen who's worked hard, lived frugally, saved, and invested what you could along the way, you need to check this out as soon as possible.Click here to see why2/22/2023Q4 2022$4.12$2.67($1.45)$2.67$519.20 million$491.50 million 11/2/2022Q3 2022$3.57$4.91+$1.34$4.91$492.92 million$516.00 million 8/3/2022Q2 2022$4.10$2.41($1.69)$2.41$461.06 million$466.90 million 5/4/2022Q1 2022$2.96$5.03+$2.07$5.03$420.02 million$461.90 million 2/24/2022Q4 2021$3.77$2.35($1.42)$2.35$427.59 million$415.20 million 11/3/2021Q3 2021$3.37$3.42+$0.05$3.42$421.45 million$444.70 million 8/4/2021Q2 2021$3.02$3.65+$0.63$3.65$378.54 million$446.50 million 5/5/2021Q1 2021$2.60$0.61($1.99)$0.61$368.31 million$379.10 million 2/23/2021Q4 2020$2.96$2.19($0.77)$2.19$362.04 million$384.90 million 10/28/2020Q3 2020$2.41$3.84+$1.43$3.84$357.95 million$380.10 million 7/29/2020Q2 2020$2.41$2.41-$2.41$339.97 million$362.00 million 4/29/2020Q1 2020$2.43$3.12+$0.69$3.12$343.68 million$356.30 million 2/26/2020Q4 2019$2.47$1.20($1.27)$1.20$357.14 million$311.10 million 10/30/2019Q3 2019$2.34$3.16+$0.82$3.01$342.28 million$401.50 million United Therapeutics Earnings - Frequently Asked Questions When is United Therapeutics's earnings date? United Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 6th, 2024 based off last year's report dates. Learn more on UTHR's earnings history. Did United Therapeutics beat their earnings estimates last quarter? In the previous quarter, United Therapeutics (NASDAQ:UTHR) missed the analysts' consensus estimate of $6.33 by $0.48 with a reported earnings per share (EPS) of $5.85. Learn more on analysts' earnings estimate vs. UTHR's actual earnings. How can I listen to United Therapeutics's earnings conference call? The conference call for United Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read United Therapeutics's conference call transcript? The conference call transcript for United Therapeutics's latest earnings report can be read online. Read Transcript How can I view United Therapeutics's earnings report? United Therapeutics's earnings report can be found in their filing with the SEC. View SEC filing How much revenue does United Therapeutics generate each year? United Therapeutics (NASDAQ:UTHR) has a recorded annual revenue of $2.33 billion. How much profit does United Therapeutics generate each year? United Therapeutics (NASDAQ:UTHR) has a recorded net income of $984.80 million. UTHR has generated $21.15 earnings per share over the last four quarters. What is United Therapeutics's price-to-earnings ratio? United Therapeutics (NASDAQ:UTHR) has a trailing price-to-earnings ratio of 16.95 and a forward price-to-earnings ratio of 14.43. The price/earnings-to-growth ratio is 1.29. What is United Therapeutics's EPS forecast for next year? United Therapeutics's earnings are expected to grow from $24.84 per share to $27.84 per share in the next year, which is a 12.08% increase. More Earnings Resources from MarketBeat Related Companies: TEVA Earnings Results BPMC Earnings Results BBIO Earnings Results BHVN Earnings Results PRGO Earnings Results BHC Earnings Results ARWR Earnings Results ALNY Earnings Results BIIB Earnings Results INCY Earnings Results Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Micron Stock Soars as AI Demand Fuels Big Q4 Earnings BeatGameStop: Earnings Won’t Save It, Dilution Points to TroubleIs Merck Stock Undervalued After Its Colossal Earnings Growth?Polestar Lives to Fight Another Day After Q2 EarningsWhy NVIDIA’s Earnings Point to a Bullish Future for Pure StorageDoes A&F's Q2 Earnings Win Point to a Strong Holiday Season?Salesforce Beats Earnings, Raises Full-Year Profit Outlook This page (NASDAQ:UTHR) was last updated on 9/30/2024 by MarketBeat.com Staff From Our PartnersBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track reco...Genesis Gold Group | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWhat is Nvidia’s New $1 Trillion SuperProject?Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | Sponsored625,000% GainThe recent crypto correction has shaken many investors, causing panic and uncertainty. But while others are fr...Crypto Swap Profits | SponsoredAI Detects Profit Surge On MondayThis has given investors the opportunity to beat the market by 1,700% and a 100% win rate to begin the year.Monument Traders Alliance | SponsoredThe most serious warning of my careerWith the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share United Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.